Resveratrol’s hepatic symphony: conducting a multi-stage intervention in liver cancer’s progression

Abstract

The development of hepatocellular carcinoma (HCC) is a multistep process often associated with chronic hepatitis, liver fibrosis, and cirrhosis. Natural products, like resveratrol, have attracted considerable attention as anticancer drugs due to their diverse pharmacological activities. Resveratrol is a natural polyphenol present in plant foods, which has antioxidant, anti-inflammatory, anti-tumor, and anti-angiogenesis effects. The growing consensus shows that resveratrol plays a therapeutic role in liver diseases positively. The therapeutic effect observed in chronic hepatitis may be related to its ability to interfere with viral replication through PI3K/Akt, NF-κB, and MAPK signaling modulation, as well as to diminish hepatocellular injury by anti-inflammatory and antioxidant means. In liver fibrosis and cirrhosis, resveratrol decelerates the progression of fibrosis by suppressing the activation of hepatic stellate cells (HSC) and collagen production as well as by regulating signaling pathways, Hippo, Nrf2/Keap1, and SIRT1. Resveratrol also prevents tumor growth, induces apoptosis and inhibits migration, invasion and angiogenesis by various signaling pathways, which include PI3K/AKT, JNK, NF-κB, and p53 in advanced HCC. It is the first time that a multi-stage mechanism of resveratrol is presented in the development of HCC, which highlights its multi-target regulation and treatment capabilities.

Keywords

Resveratrol / Chronic hepatitis / Hepatic fibrosis / Liver cancer / Pharmacologic action

Funding

This work was supported by the Chongqing Natural Science Foundation General Project (No. 2024NSCQ-MX3514), and the Army Medical University Incubation Project (No. 2022XQN35).

Declaration of Competing Interest

These authors have no conflict of interest to declare.

Acknowledgements

We are very grateful to BioRender (BioRender.com) for providing the picture drawing platform. We would also like to thank Professor Xingwei He for his funding.

References

[1] Tabrizian P, Abdelrahim M, Schwartz M. Immunotherapy and transplantation for hepatocellular carcinoma. J Hepatol. 2024; 80(5):822-825. https://doi.org/10.1016/j.jhep.2024.01.011.

[2] Li Z, Zhang Z, Fang L, et al. Tumor microenvironment composition and related therapy in hepatocellular carcinoma. J Hepatocell Carcinoma. 2023; 10:2083-2099. https://doi.org/10.2147/jhc.S436962.

[3] Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol. 2023; 20(12):864-884. https://doi.org/10.1038/s41571—023—00825—3.

[4] Xie D, Shi J, Zhou J, et al. Clinical practice guidelines and real—life practice in hepatocellular carcinoma: a Chinese perspective. Clin Mol Hepatol. 2023; 29(2):206-216. https://doi.org/10.3350/cmh.2022.0402.

[5] Ali FEM, Ibrahim IM, Althagafy HS, et al. Role of immunotherapies and stem cell therapy in the management of liver cancer: a comprehensive review. Int Immunopharmacol. 2024; 132:112011. https://doi.org/10.1016/j.intimp.2024.112011.

[6] Chen Y, Tan X, Zhang W, et al. Natural products targeting macroautophagy signaling in hepatocellular carcinoma therapy: recent evidence and perspectives. Phytother Res. 2024; 38(3):1623-1650. https://doi.org/10.1002/ptr.8103.

[7] Bi Y, Li X, Wei H, et al. Corrigendum to “Resveratrol improves emamectin benzoate—induced pyroptosis and inflammation of Ctenopharyngodon idellus hepatic cells by alleviating oxidative stress/endoplasmic reticulum stress” [Fish Shellfish Immunol. 142 (2023) 109148]. Fish Shellfish Immunol.2024; 144:109276. https://doi.org/10.1016/j.fsi.2023.109276.

[8] Kasprzak—Drozd K, Niziński P, Kasprzak P, et al. Does resveratrol improve metabolic dysfunction—associated steatotic liver disease (MASLD)? Int J Mol Sci. 2024; 25(7):3746. https://doi.org/10.3390/ijms25073746.

[9] Prakash V, Bose C, Sunilkumar D, et al. Resveratrol as a promising nutraceutical: implications in gut microbiota modulation, inflammatory disorders, and colorectal cancer. Int J Mol Sci. 2024; 25(6):3370. https://doi.org/10.3390/ijms25063370.

[10] Godos J, Romano GL, Gozzo L, et al. Resveratrol and vascular health: evidence from clinical studies and mechanisms of actions related to its metabolites produced by gut microbiota. Front Pharmacol. 2024; 15:1368949. https://doi.org/10.3389/fphar.2024.1368949.

[11] Rauf A, Imran M, Butt MS, et al. Resveratrol as an anti—cancer agent: a review. Crit Rev Food Sci Nutr. 2018; 58(9):1428-1447. https://doi.org/10.1080/10408398.2016.1263597.

[12] Jiang Q, Yang M, Qu Z, et al. Resveratrol enhances anticancer effects of paclitaxel in HepG2 human liver cancer cells. BMC Complement Altern Med. 2017; 17(1):477. https://doi.org/10.1186/s12906—017—1956—0.

[13] Song F, Zhang Y, Pan Z, et al. Resveratrol inhibits the migration, invasion and epithelial—mesenchymal transition in liver cancer cells through up—miR—186—5p expression. J Zhejiang Univ Med Sci. 2021; 50(5):582-590. https://doi.org/10.3724/zdxbyxb—2021—0197.

[14] Danpanichkul P, Aboona MB, Sukphutanan B, et al. Incidence of liver cancer in young adults according to the global burden of disease database 2019. Hepatology. 2024; 80(4):828-843. https://doi.org/10.1097/hep.0000000000000872.

[15] Lin H, Huang YS, Fustin JM, et al. Hyperpolyploidization of hepatocyte initiates preneoplastic lesion formation in the liver. Nat Commun. 2021; 12(1):645. https://doi.org/10.1038/s41467—020—20572—8.

[16] Rezzani R, Franco C. Liver, oxidative stress and metabolic syndromes. Nutrients. 2021; 13(2):301. https://doi.org/10.3390/nu13020301.

[17] Zhang B, Zhang Y, Liu X, et al. Distinctive anti—inflammatory effects of resveratrol, dihydroresveratrol, and 3—(4—hydroxyphenyl)—propionic acid on DSS—induced colitis in pseudo—germ—free mice. Food Chem. 2023; 400:133904. https://doi.org/10.1016/j.foodchem.2022.133904.

[18] Ahmed O, Robinson MW, O’Farrelly C. Inflammatory processes in the liver: divergent roles in homeostasis and pathology. Cell Mol Immunol. 2021; 18(6):1375-1386. https://doi.org/10.1038/s41423—021—00639—2.

[19] Kubes P, Jenne C. Immune responses in the liver. Annu Rev Immunol. 2018; 36:247-277. https://doi.org/10.1146/annurev—immunol—051116—052415.

[20] Chai R, Fu H, Zheng Z, et al. Resveratrol inhibits proliferation and migration through SIRT1 mediated post—translational modification of PI3K/AKT signaling in hepatocellular carcinoma cells. Mol Med Rep. 2017; 16(6):8037-8044. https://doi.org/10.3892/mmr.2017.7612.

[21] Kim J, Shim M. COX—2 inhibitor NS—398 suppresses doxorubicin—induced p53 accumulation through inhibition of ROS—mediated JNK activation. Mol Carcinog. 2016; 55(12):2156-2167. https://doi.org/10.1002/mc.22458.

[22] Yeung YT, Aziz F, Guerrero—Castilla A, et al. Signaling pathways in inflammation and anti—inflammatory therapies. Curr Pharm Des. 2018; 24(14):1449-1484. https://doi.org/10.2174/1381612824666180327165604.

[23] Raposo TP, Beirão BC, Pang LY, et al. Inflammation and cancer: till death tears them apart. Vet J. 2015; 205(2):161-174. https://doi.org/10.1016/j.tvjl.2015.04.015.

[24] Sharma N, Sistla R, Andugulapati SB. Yohimbine ameliorates liver inflammation and fibrosis by regulating oxidative stress and Wnt/β—catenin pathway. Phytomedicine. 2024; 123:155182. https://doi.org/10.1016/j.phymed.2023.155182.

[25] Kim JY, An HJ, Kim WH, et al. Anti—fibrotic effects of synthetic oligodeoxynucleotide for TGF—β1 and Smad in an animal model of liver cirrhosis. Mol Ther Nucleic Acids. 2017; 8:250-263. https://doi.org/10.1016/j.omtn.2017.06.022.

[26] Zhang X, Wu X, Hu Q, et al. Mitochondrial DNA in liver inflammation and oxidative stress. Life Sci. 2019; 236:116464. https://doi.org/10.1016/j.lfs.2019.05.020.

[27] Poma P. NF—κB and disease. Int J Mol Sci. 2020; 21(23):9181. https://doi.org/10.3390/ijms21239181.

[28] Cooke GS, Flower B, Cunningham E, et al. Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update. Lancet Gastroenterol Hepatol. 2024; 9(4):346-365. https://doi.org/10.1016/s2468—1253(23)00321—7.

[29] Pondé RAA, Amorim GSP. Elimination of the hepatitis B virus: a goal, a challenge. Med Res Rev. 2024; 44:2015-2034. https://doi.org/10.1002/med.22030.

[30] Niepmann M. Hepatitis C virus RNA translation. Curr Top Microbiol Immunol. 2013; 369:143-166. https://doi.org/10.1007/978—3—642—27340—7_6.

[31] Jeng WJ, Papatheodoridis GV, Lok ASF. Hepatitis B. Lancet. 2023; 401(10381):1039-1052. https://doi.org/10.1016/s0140—6736(22)01468—4.

[32] Parvez MK, Arbab AH, Al—Dosari MS, et al. Antiviral natural products against chronic hepatitis B: recent developments. Curr Pharm Des. 2016; 22(3):286-293. https://doi.org/10.2174/1381612822666151112152733.

[33] Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut. 2015; 64(12):1972-1984. https://doi.org/10.1136/gutjnl—2015—309809.

[34] Lin CL, Kao JH. Natural history of acute and chronic hepatitis B: the role of HBV genotypes and mutants. Best Pract Res Clin Gastroenterol. 2017; 31(3):249-255. https://doi.org/10.1016/j.bpg.2017.04.010.

[35] He Y, Wang H, Lin S, et al. Advanced effect of curcumin and resveratrol on mitigating hepatic steatosis in metabolic associated fatty liver disease via the PI3K/AKT/mTOR and HIF—1/VEGF cascade. Biomed Pharmacother. 2023; 165:115279. https://doi.org/10.1016/j.biopha.2023.115279.

[36] Pan P, Li J, Lin W, et al. Effects of resveratrol on hepatitis B virus replication: in vitro and in vivo experiments. Intervirology. 2022; 65(4):206-214. https://doi.org/10.1159/000525807.

[37] Alhusaini AM, Alshehri SM, Sarawi WS, et al. Implication of MAPK, lipocalin—2, and Fas in the protective action of liposomal resveratrol against isoproterenol—induced kidney injury. Saudi Pharm J. 2024; 32(1):101907. https://doi.org/10.1016/j.jsps.2023.101907.

[38] Darvishi M, Nouri M, Rahimi R, et al. A systematic review of the impact of resveratrol on viral hepatitis and chronic viral hepatitis—related hepatocellular carcinoma. Curr Mol Med. 2024; 25(5):589-604. https://doi.org/10.2174/0115665240284347240125072555.

[39] Nallasamy P, Kang ZY, Sun X, et al. Natural compound resveratrol attenuates TNF—alpha—induced vascular dysfunction in mice and human endothelial cells: the involvement of the NF—κB signaling pathway. Int J Mol Sci. 2021;22(22):12486. https://doi.org/10.3390/ijms222212486.

[40] Tian Y, Ma J, Wang W, et al. Resveratrol supplement inhibited the NF—κB inflammation pathway through activating AMPKα—SIRT1 pathway in mice with fatty liver. Mol Cell Biochem. 2016; 422(1—2):75-84. https://doi.org/10.1007/s11010—016—2807—x.

[41] Kortam MA, Ali BM, Fathy N. The deleterious effect of stress—induced depression on rat liver: protective role of resveratrol and dimethyl fumarate via inhibiting the MAPK/ERK/JNK pathway. J Biochem Mol Toxicol. 2021; 35(1):e22627. https://doi.org/10.1002/jbt.22627.

[42] Fei J, Qin X, Ma H, et al. Resveratrol ameliorates deep vein thrombosis—induced inflammatory response through inhibiting HIF—1α/NLRP3 pathway. Inflammation. 2022; 45(6):2268-2279. https://doi.org/10.1007/s10753—022—01689—y.

[43] Totonchi H, Mokarram P, Karima S, et al. Resveratrol promotes liver cell survival in mice liver—induced ischemia—reperfusion through unfolded protein response: a possible approach in liver transplantation. BMC Pharmacol Toxicol. 2022; 23(1):74. https://doi.org/10.1186/s40360—022—00611—4.

[44] Piermatteo L, D’Anna S, Bertoli A, et al. Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine—escape mutations in HBV genotype—D: potential impact on HBsAg detection/quantification and vaccination strategies. Emerg Microbes Infect. 2023; 12(1):2219347. https://doi.org/10.1080/22221751.2023.2219347.

[45] Su J, Brunner L, Ates Oz E, et al. Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV—carrier mouse models. J Hepatol. 2023; 78(4):717-730. https://doi.org/10.1016/j.jhep.2022.12.013.

[46] Lin HC, Chen YF, Hsu WH, et al. Resveratrol helps recovery from fatty liver and protects against hepatocellular carcinoma induced by hepatitis B virus X protein in a mouse model. Cancer Prev Res (Phila). 2012; 5(7):952-962. https://doi.org/10.1158/1940—6207.Capr—12—0001.

[47] Gao X, Xu YX, Janakiraman N, et al. Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell—mediated cytotoxicity, and cytokine production. Biochem Pharmacol. 2001; 62(9):1299-1308. https://doi.org/10.1016/s0006—2952(01)00775—4.

[48] Fuggetta MP, Bordignon V, Cottarelli A, et al. Downregulation of proinflammatory cytokines in HTLV—1—infected T cells by resveratrol. J Exp Clin Cancer Res. 2016; 35(1):118. https://doi.org/10.1186/s13046—016—0398—8.

[49] Sinha S, Hassan N, Schwartz RE. Organelle stress and alterations in interorganelle crosstalk during liver fibrosis. Hepatology. 2024; 79(2):482-501. https://doi.org/10.1097/hep.0000000000000012.

[50] Sun YD, Zhang H, Li YM, et al. Abnormal metabolism in hepatic stellate cells: pandora’s box of MAFLD related hepatocellular carcinoma. Biochim Biophys Acta Rev Cancer. 2024; 1879(2):189086. https://doi.org/10.1016/j.bbcan.2024.189086.

[51] Peiseler M, Schwabe R, Hampe J, et al. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease: novel insights into cellular communication circuits. J Hepatol. 2022; 77(4):1136-1160. https://doi.org/10.1016/j.jhep.2022.06.012.

[52] Ramos—Tovar E, Muriel P. Molecular mechanisms that link oxidative stress, inflammation, and fibrosis in the liver. Antioxidants (Basel). 2020; 9(12):1279. https://doi.org/10.3390/antiox9121279.

[53] Lee KC, Wu PS, Lin HC. Pathogenesis and treatment of non—alcoholic steatohepatitis and its fibrosis. Clin Mol Hepatol. 2023; 29(1):77-98. https://doi.org/10.3350/cmh.2022.0237.

[54] Kong M, Zhou J, Kang A, et al. Histone methyltransferase Suv39h1 regulates hepatic stellate cell activation and is targetable in liver fibrosis. Gut. 2024; 73(5):810-824. https://doi.org/10.1136/gutjnl—2023—329671.

[55] Kim JW, Kim YJ. The evidence—based multifaceted roles of hepatic stellate cells in liver diseases: a concise review. Life Sci. 2024; 344:122547. https://doi.org/10.1016/j.lfs.2024.122547.

[56] Li C, Zhang R, Zhan Y, et al. Resveratrol inhibits hepatic stellate cell activation via the Hippo pathway. Mediators Inflamm. 2021; 2021:3399357. https://doi.org/10.1155/2021/3399357.

[57] Zhang DQ, Sun P, Jin Q, et al. Resveratrol regulates activated hepatic stellate cells by modulating NF—κB and the PI3K/Akt signaling pathway. J Food Sci. 2016; 81(1):H240-H245. https://doi.org/10.1111/1750—3841.13157.

[58] Souza IC, Martins LA, Coelho BP, et al. Resveratrol inhibits cell growth by inducing cell cycle arrest in activated hepatic stellate cells. Mol Cell Biochem. 2008; 315(1—2):1-7. https://doi.org/10.1007/s11010—008—9781—x.

[59] Xia Y, Luo Q, Gao Q, et al. SIRT1 activation ameliorates rhesus monkey liver fibrosis by inhibiting the TGF—β/Smad signaling pathway. Chem Biol Interact. 2024; 394:110979. https://doi.org/10.1016/j.cbi.2024.110979.

[60] Lalle G, Twardowski J, Grinberg—Bleyer Y. NF—κB in cancer immunity: friend or foe? Cells. 2021; 10(2):355. https://doi.org/10.3390/cells10020355.

[61] Inzaugarat ME, Johnson CD, Holtmann TM, et al. NLR family pyrin domain—containing 3 inflammasome activation in hepatic stellate cells induces liver fibrosis in mice. Hepatology. 2019; 69(2):845-859. https://doi.org/10.1002/hep.30252.

[62] Abozaid OAR, Sallam MW, El—Sonbaty S, et al. Resveratrol—selenium nanoparticles alleviate neuroinflammation and neurotoxicity in a rat model of Alzheimer’s disease by regulating Sirt1/miRNA—134/GSK3β expression. Biol Trace Elem Res. 2022; 200(12):5104-5114. https://doi.org/10.1007/s12011—021—03073—7.

[63] Wang LF, Miao LJ, Wang XN, et al. CD38 deficiency suppresses adipogenesis and lipogenesis in adipose tissues through activating Sirt1/PPARγ signaling pathway. J Cell Mol Med. 2018; 22(1):101-110. https://doi.org/10.1111/jcmm.13297.

[64] Chen Y, Wang Y, Yang Y, et al. A molecular—logic gate for COX—2 and NAT based on conformational and structural changes: visualizing the progression of liver disease. Chem Sci. 2020; 11(24):6209-6216. https://doi.org/10.1039/d0sc00574f.

[65] Yang CM, Chen YW, Chi PL, et al. Resveratrol inhibits BK—induced COX—2 transcription by suppressing acetylation of AP—1 and NF—κB in human rheumatoid arthritis synovial fibroblasts. Biochem Pharmacol. 2017; 132:77-91. https://doi.org/10.1016/j.bcp.2017.03.003.

[66] Wang J, He F, Chen L, et al. Resveratrol inhibits pulmonary fibrosis by regulating miR—21 through MAPK/AP—1 pathways. Biomed Pharmacother. 2018; 105:37-44. https://doi.org/10.1016/j.biopha.2018.05.104.

[67] Ma C, Wang Y, Dong L, et al. Anti—inflammatory effect of resveratrol through the suppression of NF—κB and JAK/STAT signaling pathways. Acta Biochim Biophys Sin (Shanghai). 2015; 47(3):207-213. https://doi.org/10.1093/abbs/gmu135.

[68] Che Z, Zhou Z, Li SQ, et al. ROS/RNS as molecular signatures of chronic liver diseases. Trends Mol Med. 2023; 29(11):951-967. https://doi.org/10.1016/j.molmed.2023.08.001.

[69] Szekeres T, Saiko P, Fritzer—Szekeres M, et al. Chemopreventive effects of resveratrol and resveratrol derivatives. Ann NY Acad Sci. 2011; 1215:89-95. https://doi.org/10.1111/j.1749—6632.2010.05864.x.

[70] Fu X, Li M, Tang C, et al. Targeting of cancer cell death mechanisms by resveratrol: a review. Apoptosis. 2021; 26(11—12):561-573. https://doi.org/10.1007/s10495—021—01689—7.

[71] Chupradit S, Bokov D, Zamanian MY, et al. Hepatoprotective and therapeutic effects of resveratrol: a focus on anti—inflammatory and antioxidative activities. Fundam Clin Pharmacol. 2022; 36(3):468-485. https://doi.org/10.1111/fcp.12746.

[72] Shahcheraghi SH, Salemi F, Small S, et al. Resveratrol regulates inflammation and improves oxidative stress via Nrf2 signaling pathway: therapeutic and biotechnological prospects. Phytother Res. 2023; 37(4):1590-1605. https://doi.org/10.1002/ptr.7754.

[73] Farkhondeh T, Folgado SL, Pourbagher—Shahri AM, et al. The therapeutic effect of resveratrol: focusing on the Nrf2 signaling pathway. Biomed Pharmacother. 2020; 127:110234. https://doi.org/10.1016/j.biopha.2020.110234.

[74] Mostafa DK, Eissa MM, Ghareeb DA, et al. Resveratrol protects against Schistosoma mansoni—induced liver fibrosis by targeting the Sirt—1/NF—κB axis. Inflammopharmacology. 2024; 32(1):763-775. https://doi.org/10.1007/s10787—023—01382—y.

[75] Meng H, Yu Y, Xie E, et al. Hepatic HDAC3 regulates systemic iron homeostasis and ferroptosis via the Hippo signaling pathway. Research. 2023; 6:0281. https://doi.org/10.34133/research.0281.

[76] Du K, Maeso—Díaz R, Oh SH, et al. Targeting YAP—mediated HSC death susceptibility and senescence for treatment of liver fibrosis. Hepatology. 2023; 77(6):1998-2015. https://doi.org/10.1097/hep.0000000000000326.

[77] Zhang J, Ping J, Jiang N, et al. Resveratrol inhibits hepatic stellate cell activation by regulating autophagy and apoptosis through the SIRT1 and JNK signaling pathways. J Food Biochem. 2022; 46(12):e14463. https://doi.org/10.1111/jfbc.14463.

[78] Ungurianu A, Zanfirescu A, Margină D. Sirtuins, resveratrol and the intertwining cellular pathways connecting them. Ageing Res Rev. 2023; 88:101936. https://doi.org/10.1016/j.arr.2023.101936.

[79] Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022; 77(6):1598-1606. https://doi.org/10.1016/j.jhep.2022.08.021.

[80] Gao J, Ma F, Wang X, et al. Combination of dihydroartemisinin and resveratrol effectively inhibits cancer cell migration via regulation of the DLC1/TCTP/Cdc42 pathway. Food Funct. 2020;11(11):9573-9584. https://doi.org/10.1039/d0fo00996b.

[81] Liang S, Bo H, Zhang Y, et al. Alizarin, an agonist of the AHR receptor, enhances CYP1A1 enzyme activity and induces transcriptional changes in hepatoma cells. Molecules. 2023; 28(21):7373. https://doi.org/10.3390/molecules28217373.

[82] Ciolino HP, Yeh GC. The effects of resveratrol on CYP1A1 expression and aryl hydrocarbon receptor function in vitro. Adv Exp Med Biol. 2001; 492:183-193. https://doi.org/10.1007/978—1—4615—1283—7_14.

[83] Gorospe CM, Carvalho G, Herrera Curbelo A, et al. Mitochondrial membrane potential acts as a retrograde signal to regulate cell cycle progression. Life Sci Alliance. 2023; 6(12):202302091. https://doi.org/10.26508/lsa.202302091.

[84] Ou X, Chen Y, Cheng X, et al. Potentiation of resveratrol—induced apoptosis by matrine in human hepatoma HepG2 cells. Oncol Rep. 2014; 32(6):2803-2809. https://doi.org/10.3892/or.2014.3512.

[85] Yu L, Sun ZJ, Wu SL, et al. Effect of resveratrol on cell cycle proteins in murine transplantable liver cancer. World J Gastroenterol. 2003; 9(10):2341-2343. https://doi.org/10.3748/wjg.v9.i10.2341.

[86] Shankar S, Singh G, Srivastava RK. Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Front Biosci. 2007; 12:4839-4854. https://doi.org/10.2741/2432.

[87] Wang G, Jiang X, Torabian P, et al. Investigating autophagy and intricate cellular mechanisms in hepatocellular carcinoma: emphasis on cell death mechanism crosstalk. Cancer Lett. 2024; 588:216744. https://doi.org/10.1016/j.canlet.2024.216744.

[88] Yao X, Liu Y, Mao M, et al. Calorie restriction mimetic, resveratrol, attenuates hepatic ischemia and reperfusion injury through enhancing efferocytosis of macrophages via AMPK/STAT3/S1PR1 pathway. J Nutr Biochem. 2024; 126:109587. https://doi.org/10.1016/j.jnutbio.2024.109587.

[89] Xia C, Wang G, Chen L, et al. Trans—gnetin H isolated from the seeds of Paeonia species induces autophagy via inhibiting mTORC1 signalling through AMPK activation. Cell Prolif. 2023; 56(3):e13360. https://doi.org/10.1111/cpr.13360.

[90] Brockmueller A, Buhrmann C, Moravejolahkami AR, et al. Resveratrol and p53: how are they involved in CRC plasticity and apoptosis? J Adv Res. 2024; 66:181-195. https://doi.org/10.1016/j.jare.2024.01.005.

[91] Wang H, Guo M, Wei H, et al. Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transduct Target Ther. 2023; 8(1):92. https://doi.org/10.1038/s41392—023—01347—1.

[92] Khezri MR, Hsueh HY, Mohammadipanah S, et al. The interplay between the PI3K/AKT pathway and circadian clock in physiologic and cancer—related pathologic conditions. Cell Prolif. 2024:e13608. https://doi.org/10.1111/cpr.13608.

[93] Skonieczna M, Adamiec—Organisciok M, Hudy D, et al. Hepatocellular cancer cell lines, Hep—3B and Hep—G2 display the pleiotropic response to resveratrol and berberine. Adv Med Sci. 2022; 67(2):379-385. https://doi.org/10.1016/j.advms.2022.09.003.

[94] Baek SY, Hwang UW, Suk HY, et al. Hemistepsin A inhibits cell proliferation and induces G₀/G₁—phase arrest, cellular senescence and apoptosis via the AMPK and p53/p21 signals in human hepatocellular carcinoma. Biomolecules. 2020; 10(5):713. https://doi.org/10.3390/biom10050713.

[95] Cecchinato V, Chiaramonte R, Nizzardo M, et al. Resveratrol—induced apoptosis in human T—cell acute lymphoblastic leukaemia MOLT—4 cells. Biochem Pharmacol. 2007; 74(11):1568-1574. https://doi.org/10.1016/j.bcp.2007.08.001.

[96] Guo A, Chang Y, Lin J, et al. Resveratrol enhances anticancer effects of silybin on HepG2 cells and H22 tumor—bearing mice via inducing G₂/M phase arrest and increasing Bax/Bcl—2 ratio. Comb Chem High Throughput Screen. 2024; 28(1):89-98. https://doi.org/10.2174/0113862073263408231101105647.

[97] van Ginkel PR, Yan MB, Bhattacharya S, et al. Natural products induce a G protein—mediated calcium pathway activating p53 in cancer cells. Toxicol Appl Pharmacol. 2015; 288(3):453-462. https://doi.org/10.1016/j.taap.2015.08.016.

[98] Um HJ, Bae JH, Park JW, et al. Differential effects of resveratrol and novel resveratrol derivative, HS—1793, on endoplasmic reticulum stress—mediated apoptosis and Akt inactivation. Int J Oncol. 2010; 36(4):1007-1013. https://doi.org/10.3892/ijo_00000581.

[99] Choi HY, Chong SA, Nam MJ. Resveratrol induces apoptosis in human SK—Hep—1 hepatic cancer cells. Cancer Genomics Proteomics. 2009; 6(5):263-268.

[100] Umthong S, Lynch B, Timilsina U, et al. Elucidating the antiviral mechanism of different MARCH factors. mBio. 2021; 12(2):e03264-20. https://doi.org/10.1128/mBio.03264—20.

[101] Dai H, Li M, Yang W, et al. Resveratrol inhibits the malignant progression of hepatocellular carcinoma via MARCH1—induced regulation of PTEN/AKT signaling. Aging (Albany NY). 2020;12(12):11717-11731. https://doi.org/10.18632/aging.103338.

[102] Chen P, Yao L, Yuan M, et al. Mitochondrial dysfunction: a promising therapeutic target for liver diseases. Genes Dis. 2024; 11(3):101115. https://doi.org/10.1016/j.gendis.2023.101115.

[103] Wu L, Chen Q, Dong B, et al. Resveratrol alleviates lipopolysaccharide—induced liver injury by inducing SIRT1/P62—mediated mitophagy in gibel carp (Carassius gibelio). Front Immunol. 2023; 14:1177140. https://doi.org/10.3389/fimmu.2023.1177140.

[104] Chen N, Hu M, Jiang T, et al. Insights into the molecular mechanisms, structure—activity relationships and application prospects of polysaccharides by regulating Nrf2—mediated antioxidant response. Carbohydr Polym. 2024; 333:122003. https://doi.org/10.1016/j.carbpol.2024.122003.

[105] Yu Q, Dong L, Li Y, et al. SIRT1 and HIF1α signaling in metabolism and immune responses. Cancer Lett. 2018; 418:20-26. https://doi.org/10.1016/j.canlet.2017.12.035.

[106] Fröjdö S, Durand C, Molin L, et al. Phosphoinositide 3—kinase as a novel functional target for the regulation of the insulin signaling pathway by SIRT1. Mol Cell Endocrinol. 2011; 335(2):166-176. https://doi.org/10.1016/j.mce.2011.01.008.

[107] Ning Y, Dou X, Wang Z, et al. SIRT3: a potential therapeutic target for liver fibrosis. Pharmacol Ther. 2024; 257:108639. https://doi.org/10.1016/j.pharmthera.2024.108639.

[108] Saleh AK, El—Mahdy NA, El—Masry TA, et al. Trifluoperazine mitigates cyclophosphamide—induced hepatic oxidative stress, inflammation, and apoptosis in mice by modulating the AKT/mTOR—driven autophagy and Nrf2/HO—1 signaling cascades. Life Sci. 2024; 344:122566. https://doi.org/10.1016/j.lfs.2024.122566.

[109] Jia S, Si R, Liu G, et al. Diosgenin protects against cationic bovine serum albumin—induced membranous glomerulonephritis by attenuating oxidative stress and renal inflammation via the NF—κB pathway. Pharm Biol. 2024; 62(1):285-295. https://doi.org/10.1080/13880209.2024.2330602.

[110] Antar SA, Ashour NA, Marawan ME, et al. Fibrosis: types, effects, markers, mechanisms for disease progression, and its relation with oxidative stress, immunity, and inflammation. Int J Mol Sci. 2023; 24(4):4004. https://doi.org/10.3390/ijms24044004.

[111] Mamun AA, Shao C, Geng P, et al. Polyphenols targeting NF—κB pathway in neurological disorders: what we know so far? Int J Biol Sci. 2024; 20(4):1332-1355. https://doi.org/10.7150/ijbs.90982.

[112] Carrera—Aguado I, Marcos—Zazo L, Carrancio—Salán P, et al. The inhibition of vessel co—option as an emerging strategy for cancer therapy. Int J Mol Sci. 2024; 25(2):921. https://doi.org/10.3390/ijms25020921.

[113] Qin Q, Li Z, Liu R, et al. Effects of resveratrol on HIF—1α/VEGF pathway and apoptosis in vitrified duck ovary transplantation. Theriogenology. 2023; 210:84-93. https://doi.org/10.1016/j.theriogenology.2023.06.037.

[114] Olaso E, Benedicto A, Lopategi A, et al. A synthetic analog of resveratrol inhibits the proangiogenic response of liver sinusoidal cells during hepatic metastasis. Biomol Ther (Seoul). 2022; 30(2):162-169. https://doi.org/10.4062/biomolther.2021.062.

[115] Shaw P, Dwivedi SKD, Bhattacharya R, et al. VEGF signaling: role in angiogenesis and beyond. Biochim Biophys Acta Rev Cancer. 2024; 1879(2):189079. https://doi.org/10.1016/j.bbcan.2024.189079.

[116] Wlodarczyk J, Leng A, Abadchi SN, et al. Transfection of hypoxia—inducible factor—1α mRNA upregulates the expression of genes encoding angiogenic growth factors. Sci Rep. 2024; 14(1):6738. https://doi.org/10.1038/s41598—024—54941—w.

[117] Ji K, Li Z, Lei Y, et al. Resveratrol attenuates retinal ganglion cell loss in a mouse model of retinal ischemia reperfusion injury via multiple pathways. Exp Eye Res. 2021; 209:108683. https://doi.org/10.1016/j.exer.2021.108683.

[118] Zhang H, Yang R. Resveratrol inhibits VEGF gene expression and proliferation of hepatocarcinoma cells. Hepatogastroenterology. 2014; 61(130):410-412.

[119] Zhang Q, Tang X, Lu QY, et al. Resveratrol inhibits hypoxia—induced accumulation of hypoxia—inducible factor—1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol Cancer Ther. 2005; 4(10):1465-1474. https://doi.org/10.1158/1535—7163.Mct—05—0198.

[120] Zhang M, Li W, Yu L, et al. The suppressive effect of resveratrol on HIF—1α and VEGF expression after warm ischemia and reperfusion in rat liver. PLoS One. 2014; 9(10):e109589. https://doi.org/10.1371/journal.pone.0109589.

[121] Yan Y, Zhou C, Li J, et al. Resveratrol inhibits hepatocellular carcinoma progression driven by hepatic stellate cells by targeting Gli—1. Mol Cell Biochem. 2017; 434(1—2):17-24. https://doi.org/10.1007/s11010—017—3031—z.

[122] Hajinejad M, Pasbakhsh P, Omidi A, et al. Resveratrol pretreatment enhanced homing of SDF—1α—preconditioned bone marrow—derived mesenchymal stem cells in a rat model of liver cirrhosis. J Cell Biochem. 2018; 119(3):2939-2950. https://doi.org/10.1002/jcb.26500.

[123] Grillet B, Pereira RVS, Van Damme J, et al. Matrix metalloproteinases in arthritis: towards precision medicine. Nat Rev Rheumatol. 2023; 19(6):363-377. https://doi.org/10.1038/s41584—023—00966—w.

[124] Hu Y, Sun CY, Huang J, et al. Antimyeloma effects of resveratrol through inhibition of angiogenesis. Chin Med J (Engl). 2007; 120(19):1672-1677. https://doi.org/10.1097/00029330—200710010—00006.

[125] Alshehri FS, Bashmeil AA, Alamar IA, et al. The natural anticoagulant protein S: hemostatic functions and deficiency. Platelets. 2024; 35(1):2337907. https://doi.org/10.1080/09537104.2024.2337907.

[126] Feng R, Cheng D, Chen X, et al. Identification and validation of palmitoylation metabolism—related signature for liver hepatocellular carcinoma. Biochem Biophys Res Commun. 2024; 692:149325. https://doi.org/10.1016/j.bbrc.2023.149325.

[127] Hiroto Y, Tadokoro K, Tsuda T, et al. Resveratrol, a phytoestrogen found in red wine, down—regulates protein S expression in HepG2 cells. Thromb Res. 2011; 127(1):e1-e7. https://doi.org/10.1016/j.thromres.2010.09.010.

[128] Sarfraz M, Arafat M, Zaidi SHH, et al. Resveratrol—laden nano—systems in the cancer environment: views and reviews. Cancers (Basel). 2023; 15(18):4499. https://doi.org/10.3390/cancers15184499.

[129] Ren B, Kwah MX, Liu C, et al. Resveratrol for cancer therapy: challenges and future perspectives. Cancer Lett. 2021; 515:63-72. https://doi.org/10.1016/j.canlet.2021.05.001.

[130] El—Sherbeni AA, El—Kadi AO. Repurposing resveratrol and fluconazole to modulate human cytochrome P450—mediated arachidonic acid metabolism. Mol Pharm. 2016; 13(4):1278-1288. https://doi.org/10.1021/acs.molpharmaceut.5b00873.

[131] Angellotti G, Di Prima G, D’Agostino F, et al. Multicomponent antibiofilm lipid nanoparticles as novel platform to ameliorate resveratrol properties: preliminary outcomes on fibroblast proliferation and migration. Int J Mol Sci. 2023; 24(9):8382. https://doi.org/10.3390/ijms24098382.

[132] Singh G, Pai RS. Trans—resveratrol self—nano—emulsifying drug delivery system (SNEDDS) with enhanced bioavailability potential: optimization, pharmacokinetics and in situ single pass intestinal perfusion (SPIP) studies. Drug Deliv. 2015; 22(4):522-530. https://doi.org/10.3109/10717544.2014.885616.

[133] Lee CW, Yen FL, Huang HW, et al. Resveratrol nanoparticle system improves dissolution properties and enhances the hepatoprotective effect of resveratrol through antioxidant and anti—inflammatory pathways. J Agric Food Chem. 2012; 60(18):4662-4671. https://doi.org/10.1021/jf2050137.

[134] Cottart CH, Nivet—Antoine V, Laguillier—Morizot C, et al. Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res. 2010; 54(1):7-16. https://doi.org/10.1002/mnfr.200900437.

[135] Tseilikman VE, Fedotova JO, Tseilikman OB, et al. Resistance to resveratrol treatment in experimental PTSD is associated with abnormalities in hepatic metabolism of glucocorticoids. Int J Mol Sci. 2023; 24(11):9333. https://doi.org/10.3390/ijms24119333.

[136] Mahjabeen W, Khan DA, Mirza SA. Role of resveratrol supplementation in regulation of glucose hemostasis, inflammation and oxidative stress in patients with diabetes mellitus type 2: a randomized, placebo—controlled trial. Complement Ther Med. 2022; 66:102819. https://doi.org/10.1016/j.ctim.2022.102819.

[137] Qasem RJ. The estrogenic activity of resveratrol: a comprehensive review of in vitro and in vivo evidence and the potential for endocrine disruption. Crit Rev Toxicol. 2020; 50(5):439-462. https://doi.org/10.1080/10408444.2020.1762538.

[138] Zhao X, Su H, Chen H, et al. Integrated serum pharmacochemistry and network pharmacology to explore the mechanism of Yi—Shan—Hong Formula in alleviating chronic liver injury. Phytomedicine. 2024; 128:155439. https://doi.org/10.1016/j.phymed.2024.155439.

[139] Zhang C, Sun TT, Lv Y, et al. A Chinese herbal formula Kesuting Syrup against COVID—19: leveraging multidimensional computations in network pharmacology—driven experimental and clinical trials. Clin Transl Med. 2024; 14(2):e1569. https://doi.org/10.1002/ctm2.1569.

[140] Liu HS, Pan CE, Yang W, et al. Antitumor and immunomodulatory activity of resveratrol on experimentally implanted tumor of H22 in Balb/c mice. World J Gastroenterol. 2003; 9(7):1474-1476. https://doi.org/10.3748/wjg.v9.i7.1474.

[141] Zhang Q, Huang H, Zheng F, et al. Resveratrol exerts antitumor effects by downregulating CD8⁺CD122⁺Tregs in murine hepatocellular carcinoma. Oncoimmunology. 2020; 9(1):1829346. https://doi.org/10.1080/2162402X.2020.1829346.

[142] Chen L, Musa AE. Boosting immune system against cancer by resveratrol. Phytother Res. 2021; 35(10):5514-5526. https://doi.org/10.1002/ptr.7189.

[143] Gao M, Deng C, Dang F. Synergistic antitumor effect of resveratrol and sorafenib on hepatocellular carcinoma through PKA/AMPK/eEF2K pathway. Food Nutr Res. 2021; 65:3602. https://doi.org/10.29219/fnr.v65.3602.

[144] Huang X, Wang Y, Yang W, et al. Regulation of dietary polyphenols on cancer cell pyroptosis and the tumor immune microenvironment. Front Nutr. 2022; 9:974896. https://doi.org/10.3389/fnut.2022.974896.

[145] Shi Y, Li Y, Huang C, et al. Resveratrol enhances HBV replication through activating Sirt1—PGC—1α—PPARα pathway. Sci Rep. 2016; 6:24744. https://doi.org/10.1038/srep24744.

[146] Nakamura M, Saito H, Ikeda M, et al. An antioxidant resveratrol significantly enhanced replication of hepatitis C virus. World J Gastroenterol. 2010; 16(2):184-192. https://doi.org/10.3748/wjg.v16.i2.184.